Literature DB >> 19076624

Sebaceous carcinoma: the great masquerader: emgerging concepts in diagnosis and treatment.

William Buitrago1, Aaron K Joseph.   

Abstract

Sebaceous carcinoma (SC) is a rare tumor with a high rate of local recurrence and metastasis to lymph nodes and organs. The majority of SCs occur in the periocular region frequently presenting as painless, round subcutaneous nodules with a high tendency of diffuse and invasive growth in the eyelid and conjunctiva. It frequently masquerades as inflammatory conditions or as other tumors leading to delay in diagnosis, inappropriate treatment and increased morbidity and mortality. Sebaceous carcinoma is associated with Muir-Torre syndrome, a genetic condition presenting with sebaceous skin tumors associated with internal malignancy. Therefore, SC patients must be carefully evaluated and referred to an internist or gastroenterologist when indicated. Surgery is the definitive therapy for SC. In recent years, less radical surgical strategies are being used with improved outcomes. Current studies demonstrate that Mohs micrographic surgery (MMS) provides maximal tissue conservation and lower recurrence rates. Greater awareness and understanding of SC and its behavior has led to earlier diagnosis and appropriate treatment.

Entities:  

Mesh:

Year:  2008        PMID: 19076624     DOI: 10.1111/j.1529-8019.2008.00247.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  31 in total

1.  Ocular sebaceous carcinoma, the great masquerader.

Authors:  Abdullah Al-Mujaini; Buthaina Sabt; Aisha Al-Hamdani
Journal:  Oman Med J       Date:  2009-07

2.  Muir-torre syndrome: a case report.

Authors:  Heather J Higgins; Melissa Voutsalath; Jean M Holland
Journal:  J Clin Aesthet Dermatol       Date:  2009-08

Review 3.  Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications.

Authors:  Sara C Shalin; Stephen Lyle; Eduardo Calonje; Alexander J F Lazar
Journal:  Histopathology       Date:  2010-01       Impact factor: 5.087

Review 4.  The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland.

Authors:  Erich Knop; Nadja Knop; Thomas Millar; Hiroto Obata; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

5.  p53 staining correlates with tumor type and location in sebaceous neoplasms.

Authors:  Sara C Shalin; Aniket Sakharpe; Stephen Lyle; Dina Lev; Eduardo Calonje; Alexander J Lazar
Journal:  Am J Dermatopathol       Date:  2012-04       Impact factor: 1.533

6.  Skin adnexal carcinoma of the head and neck: a retrospective study in a tertiary referral center.

Authors:  Hanneke Stam; Bart A van de Wiel; W Martin C Klop; Biljana Zupan-Kajcovski; Soe Janssens; M Baris Karakullukcu; Vincent van der Noort; Peter J F M Lohuis
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-16       Impact factor: 2.503

7.  CDKN2A, CDK1, and CCNE1 overexpression in sebaceous gland carcinoma of eyelid.

Authors:  Tatsuya Yunoki; Tetsushi Hirano; Yoshiaki Tabuchi; Yukihiro Furusawa; Misako Torigoe; Takahiko Nakajima; Johji Imura; Atsushi Hayashi
Journal:  Int Ophthalmol       Date:  2019-09-30       Impact factor: 2.031

8.  Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.

Authors:  Min Joung Lee; Namju Kim; Ho-Kyung Choung; Ji-Young Choe; Sang In Khwarg; Ji Eun Kim
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-04       Impact factor: 4.553

Review 9.  Parotid Sebaceous Carcinoma in Patient with Muir Torre Syndrome, Caused by MSH2 Mutation.

Authors:  Iyer Vishwas Neelakantan; Silvana Di Palma; C E T Smith; A McCoombe
Journal:  Head Neck Pathol       Date:  2015-11-17

10.  Sebaceous Gland Carcinoma of the Lower Eyelid Reconstructed with a Composite Flap: A Case Report.

Authors:  Surya Rao Rao Venkata Mahipathy; Alagar Raja Durairaj; Kanmani Kothandaraman; Vimal Chander Rajamanohar; Aarthi Prabakaran
Journal:  J Clin Diagn Res       Date:  2016-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.